E
Elusys Therapeutics
Elusys Therapeutics is a private company focused on the development of antibody therapeutics for the treatment of infectious disease
About Elusys Therapeutics
Elusys Therapeutics operates as a commercial-stage biopharmaceutical firm with a dedicated focus on developing antibody-based therapeutics for infectious diseases, specifically positioning itself within the biodefense sector. The company was founded in 1998 by Jeffrey Wolf, who served as its initial CEO. The foundational technology for the company stemmed from the research of Ronald P. Taylor, a professor at the University of Virginia, who developed heteropolymers designed to clear pathogens from the bloodstream.
The company's business model is centered on securing large-scale government contracts for its primary product. Elusys has been awarded over $450 million in development and procurement contracts from various U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA), the National Institute of Allergy and Infectious Disease (NIAID), and the Department of Defense (DoD). These contracts facilitate the development and supply of its product to the U.S. Strategic National Stockpile (SNS), the government's repository of medical supplies for biodefense preparedness. The company also supplies its product to the Public Health Agency of Canada. In April 2022, Elusys was acquired by Heat Biologics (now known as NightHawk Biosciences) and continues to operate as a wholly-owned subsidiary.
The principal product is ANTHIM® (obiltoxaximab), a monoclonal antibody antitoxin for treating and preventing inhalational anthrax, which is caused by the bacterium *Bacillus anthracis*. Approved by the U.S. Food and Drug Administration (FDA) in March 2016, ANTHIM functions by neutralizing the protective antigen (PA) component of the anthrax toxin. This action prevents the toxin's lethal components from entering the body's cells, thereby stopping the spread of tissue damage. ANTHIM is administered as a single intravenous infusion and is used in conjunction with appropriate antibacterial drugs for treatment, or as a prophylactic measure when other therapies are unavailable. Its FDA approval was granted under the Animal Rule, which permits efficacy data from animal studies when human trials are not ethical or feasible.
Source: Dealroom company dataNews
Open roles
Elusys Therapeutics in the Montville ecosystem
The Elusys Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
Pfizer
Invesco- MPMillennium Venture Partners
MedImmune Ventures
EW Healthcare Partners- CVCrescendo Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Elusys Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Elusys Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

